These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 25900790)
1. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement. Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790 [No Abstract] [Full Text] [Related]
2. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693 [TBL] [Abstract][Full Text] [Related]
3. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402 [TBL] [Abstract][Full Text] [Related]
4. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004 [No Abstract] [Full Text] [Related]
5. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226 [TBL] [Abstract][Full Text] [Related]
7. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151 [TBL] [Abstract][Full Text] [Related]
8. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes. Salaroli A; Loglisci G; Serrao A; Alimena G; Breccia M Ann Hematol; 2012 Nov; 91(11):1823-4. PubMed ID: 22623162 [No Abstract] [Full Text] [Related]
9. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389 [TBL] [Abstract][Full Text] [Related]
10. Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data. Dao K; Védy D; Lopez J; Staneczek O; Buclin T; Livio F Int J Hematol; 2013 Feb; 97(2):299-300. PubMed ID: 23271413 [No Abstract] [Full Text] [Related]
11. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Hughes TP; Hochhaus A; Kantarjian HM; Cervantes F; Guilhot F; Niederwieser D; le Coutre PD; Rosti G; Ossenkoppele G; Lobo C; Shibayama H; Fan X; Menssen HD; Kemp C; Larson RA; Saglio G Haematologica; 2014 Jul; 99(7):1204-11. PubMed ID: 24532039 [TBL] [Abstract][Full Text] [Related]
13. Late onset imatinib-induced Stevens-Johnson syndrome. Bois E; Holle LM; Farooq U J Oncol Pharm Pract; 2014 Dec; 20(6):476-8. PubMed ID: 24399835 [TBL] [Abstract][Full Text] [Related]
14. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy. Chalmers ZR; Ali SM; Ohgami RS; Campregher PV; Frampton GM; Yelensky R; Elvin JA; Palma NA; Erlich R; Vergilio JA; Chmielecki J; Ross JS; Stephens PJ; Hermann R; Miller VA; Miles CR Blood Cancer J; 2015 Feb; 5(2):e278. PubMed ID: 25658984 [No Abstract] [Full Text] [Related]
16. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia. Machaczka M; Gossart M Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191 [No Abstract] [Full Text] [Related]
17. Optimizing second-line therapy for chronic myeloid leukemia. Raja T Indian J Cancer; 2012; 49(1):46-56. PubMed ID: 22842168 [TBL] [Abstract][Full Text] [Related]
18. Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines. Ringel F; Kaeda J; Schwarz M; Oberender C; Grille P; Dörken B; Marque F; Manley PW; Radimerski T; le Coutre P Acta Haematol; 2014; 132(1):75-86. PubMed ID: 24504330 [TBL] [Abstract][Full Text] [Related]
19. Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy. Gambacorti-Passerini C; Piazza R Am J Hematol; 2011 Jul; 86(7):531-2. PubMed ID: 21674581 [No Abstract] [Full Text] [Related]
20. Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib. Spataro V J Clin Oncol; 2011 Jan; 29(3):e50-2. PubMed ID: 20956624 [No Abstract] [Full Text] [Related] [Next] [New Search]